Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus’ FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
Metrics to compare | GUBRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGUBRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.2x | −4.5x | −0.4x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 4.7x | 2.4x | 2.6x | |
Price / LTM Sales | 2.0x | 2.3x | 3.2x | |
Upside (Analyst Target) | 43.3% | 44.1% | 46.7% | |
Fair Value Upside | Unlock | 11.4% | 7.6% | Unlock |